With the progression of AD, there is an increase in the plasma concentrations of NfL, correlating with amyloid and tau biomarkers, MRI measurements (regarding both white and gray matter loss), as well as with cognitive performances [79]. This evidence concerns the gene MAPT and Alzheimer disease.